Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 9567393
Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid
granted -
US 9567439
Sulfur composites and polymeric materials from elemental sulfur
granted -
US 9566320
Mucin-associated surface protein as vaccine against Chagas disease
granted -
US 9566314
Extracellular vesicles comprising recombinant lysosomal transmembrane protein
granted -
US 9566251
Volatile anesthetic compositions and methods of use
granted -
US 9565857
Antimicrobial solutions
granted -
US 9565840
Fibrotic non-human animal, and use thereof
granted -
US 9567402
Internalizing human monoclonal antibodies targeting prostate and other cancer cells
granted -
US 9566310
Methods of treating muscular dystrophy
granted -
US 9567592
Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
granted -
US 9562217
Modalities for the treatment of degenerative diseases of the retina
granted -
US 9561245
Combination treatments for melanoma
granted -
US 9561256
LLP2A-bisphosphonate conjugates for osteoporosis treatment
granted -
US 9562100
Molecules with extended half-lives, compositions and uses thereof
granted -
US 9562088
Pegylated CD154 peptides and methods of inhibiting CD40 interacations with CD154
granted -
US 9562015
Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
granted -
US 9562002
STAT3 inhibitor
granted -
US 9562070
Induction of tumor immunity by variants of folate binding protein
granted -
US 9555135
Cobalt-based MRI contrast agent and imaging system
granted -
US 9556144
Compound as WNT signaling inhibitor, composition, and use thereof
granted -
US 9555159
Inorganically surface-modified polymers and methods for making and using them
granted -
US 9555114
Methods for in vivo drug delivery with porous nanostructures
granted -
US 9555086
Compositions and methods for inducing an immune response
granted -
US 9555074
Annexin II compositions
granted -
US 9555073
Use of vitelline protein B as a microencapsulating additive
granted -
US 9555100
Herpes virus vaccine and methods of use
granted -
US 9556113
Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment
granted -
US 9556131
Compositions, methods of use, and methods of treatment
granted -
US 9549905
Treatment of inflammatory and infectious skin disorders
granted -
US 9549995
Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy
granted -
US 9551713
Use of a panel of urinary cytokines to predict response to BCG therapy for bladder cancer
granted -
US 9549954
Method and composition for inducing human pluripotent stem cells
granted -
US 9550974
Derivation of embryonic stem cells
granted -
US 9549955
Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
granted -
US 9551721
Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
granted -
US 9551722
Amyloid binding agents
granted -
US 9550827
Methods for ameliorating and preventing central nervous system inflammation
granted -
US 9550078
EDAR ligand derived peptides and use thereof
granted -
US 9545461
Anti-microbial peptides and methods of use thereof
granted -
US 9545370
Bioactive compositions and methods for their preparation and use
granted -
US 9545422
Methods of inducing photosensitivity by targeting channelrhodopsin-2 and halorhodopsin to subcellular regions of retinal ganglion cells
granted -
US 9545452
Biomineral and metal binding liposomes, their synthesis, and methods of use thereof
granted -
US 9546193
Compositions and methods for 18F-fluorodeoxyglycosylamines
granted -
US 9546370
QSOX1 as an anti-neoplastic drug target
granted -
US 9540337
Gamma-glutamyl transpeptidase inhibitors and methods of use
granted -
US 9539342
Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
granted -
US 9539301
Melanotropin ligands for skin care
granted -
US 9539256
Modulators of exchange proteins directly activated by cAMP (EPACS)
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory